ALCLS Cellectis SA

Monthly information on share capital and company voting rights

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, Feb. 04, 2025 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

   
DateTotal number of shares

in the capital		Total number of voting rights
01/31/2025100,093,87388,660,571
   

For further information on Cellectis, please contact:     

Media contact:       

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contacts:       

Arthur Stril, Interim Chief Financial Officer, +1 (347) 809 5980,  

Attachment



EN
04/02/2025

Underlying

ALCLSCellectis SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cellectis SA

Ahmed Ben Salem ... (+2)
  • Ahmed Ben Salem
  • Baptiste Lebacq
FRA FRAPORT AG
ETL EUTELSAT COMMUNICATIONS SA
SCR SCOR SE
OERL OC OERLIKON CORPORATION AG
ALCLS CELLECTIS SA
BOSS HUGO BOSS AG
NOEJ NORMA GROUP SE
ERA ERAMET SA
LNZ LENZING AG
NDA AURUBIS AG
KRN KRONES AG
COFA COFACE SA
TRP TERAPLAST
MAU ETABLISSEMENTS MAUREL & PROM SA
SFQ SAF-HOLLAND SE
ADTN ADTRAN HOLDINGS INC
STM STABILUS SE
16h / 30m 16h / 30m 1 EN
Ahmed Ben Salem ... (+2)
  • Ahmed Ben Salem
  • Baptiste Lebacq
FRA FRAPORT AG
ETL EUTELSAT COMMUNICATIONS SA
SCR SCOR SE
OERL OC OERLIKON CORPORATION AG
ALCLS CELLECTIS SA
BOSS HUGO BOSS AG
NOEJ NORMA GROUP SE
ERA ERAMET SA
LNZ LENZING AG
NDA AURUBIS AG
KRN KRONES AG
COFA COFACE SA
TRP TERAPLAST
MAU ETABLISSEMENTS MAUREL & PROM SA
SFQ SAF-HOLLAND SE
ADTN ADTRAN HOLDINGS INC
STM STABILUS SE
16h / 34m 16h / 34m 1 FR
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
17h / 4m 17h / 4m 1 EN
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
17h / 12m 17h / 12m 1 FR
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis Reports Second Quarter 2025 Financial Results & Business Upd...

Cellectis Reports Second Quarter 2025 Financial Results & Business Updates Cellectis to host an Investor R&D Day in New York City on October 16, 2025: Phase 1 dataset and late-stage development strategy for lasme-cel (UCART22) in r/r B-ALL to be presented End-of-Phase 1 meetings with FDA & EMA for lasme-cel (UCART22) in r/r B-ALL completed in July 2025; on track to launch pivotal Phase 2 in H2 2025  Servier arbitration: arbitral decision expected to be rendered on or before December 15, 2025 eti-cel (UCART20x22): Phase 1 study in r/r NHL ongoing with readout expected in late 2025  AstraZene...

August 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch